Issuer Delisting; Notice of Application of New York Health Care, Inc. To Withdraw Its Common Stock, $.01 Par Value, From Listing and Registration on the Boston Stock Exchange, Inc., 7128-7129 [E5-563]
Download as PDF
<![CDATA[
7128
Federal Register / Vol. 70, No. 27 / Thursday, February 10, 2005 / Notices
approved collection of information
discussed below.
Rule 17a–4 requires approximately
6,900 active, registered exchange
members, brokers and dealers (‘‘brokerdealers’’) to preserve for prescribed
periods of time certain records required
to be made by Rule 17a–3 and other
Commission rules, and other kinds of
records which firms make or receive in
the ordinary course of business. Rule
17a–4 also permits broker-dealers to
employ, under certain conditions,
electronic storage media to maintain
these required records. The records
required to be maintained under Rule
17a–4 are used by examiners and other
representatives of the Commission to
determine whether broker-dealers are in
compliance with, and to enforce their
compliance with, the Commission’s
rules.
The staff estimates that the average
number of hours necessary for each
broker-dealer to comply with Rule 17a–
4 is 254 hours annually. Thus, the total
burden for broker-dealers is 1,752,600
hours annually. The staff believes that
compliance personnel would be charged
with ensuring compliance with
Commission regulation, including Rule
17a–4. The staff estimates that the
hourly salary of a compliance manager
is $50 per hour.1 Based upon these
numbers, the total cost of compliance
for 6,900 respondents is approximately
$87.63 million (1,752,600 yearly hours x
$50). The total burden hour decrease of
128,661 results from the decrease in the
number of respondents from 7,217 to
6,900.
An agency may not conduct or
sponsor, and a person is not required to
respond to, a collection of information
unless it displays a currently valid
control number.
General comments regarding the
above information should be directed to
the following persons: (i) Desk Officer
for the Securities and Exchange
Commission, by sending an e-mail to:
David_Rostker@omb.eop.gov; and (ii) R.
Corey Booth, Director/Chief Information
Officer, Office of Information
Technology, Securities and Exchange
Commission, 450 Fifth Street, NW.,
Washington, DC 20549. Comments must
be submitted to OMB within thirty days
of this notice.
February 4, 2005.
Margaret H. McFarland,
Deputy Secretary.
[FR Doc. E5–569 Filed 2–9–05; 8:45 am]
BILLING CODE 8010–01–P
1 This figure is based on the SIA Report on Office
Salaries In the Securities Industry 2003
(Compliance Manager) and includes 35% for
overhead charges.
VerDate jul<14>2003
16:20 Feb 09, 2005
Jkt 205001
SECURITIES AND EXCHANGE
COMMISSION
Submission for OMB Review;
Comment Request
Upon Written Request, Copies Available
From: Securities and Exchange
Commission Office of Filings and
Information Services, Washington, DC
20549.
Extensions: Schedule TO OMB Control No.
3235–0515; SEC File No. 270–456.
Notice is hereby given that pursuant
to the Paperwork Reduction Act of 1995
(44 U.S.C. 3501 et seq.), the Securities
and Exchange Commission
(‘‘Commission’’) has submitted to the
Office of Management and Budget a
request for extension of the previously
approved collection of information
discussed below.
Schedule TO must be filed by a
reporting company that makes a tender
offer for its own securities. Also,
persons other than the reporting
company making a tender offer for
equity securities registered under
Section 12 of the Exchange Act (which
offer, if consummated, would cause that
person to own over 5% of that class of
the securities) must file Schedule TO.
The purpose of Schedule TO is to
improve communications between
public companies and investors before
companies file registration statements
involving tender offer statements. This
information is made available to the
public. Information provided on
Schedule TO is mandatory.
Approximately 2,500 issuers annually
file Schedule TO and it takes 43.5 hours
to prepare for a total of 108,750 annual
burden hours. It is estimated that 50%
of the 108,750 total burden hours
(54,375 burden hours) is prepared by
the company.
An agency may not conduct or
sponsor, and a person is not required to
respond to, a collection of information
unless it displays a currently valid
control number.
Written comments regarding the
above information should be directed to
the following persons: (i) Desk Officer
for the Securities and Exchange
Commission, Office of Information and
Regulatory Affairs, Office of
Management and Budget, Room 10102,
New Executive Office Building,
Washington, DC 20503 or send an email to David_Rostker@omb.eop.gov;
and (ii) R. Corey Booth, Director/Chief
Information Officer, Office of
Information Technology, Securities and
Exchange Commission, 450 Fifth Street,
NW., Washington, DC 20549. Comments
PO 00000
Frm 00055
Fmt 4703
Sfmt 4703
must be submitted to OMB within 30
days of this notice.
Dated: February 4, 2005.
Margaret H. McFarland,
Deputy Secretary.
[FR Doc. E5–572 Filed 2–9–05; 8:45 am]
BILLING CODE 8010–01–P
SECURITIES AND EXCHANGE
COMMISSION
[File No. 1–12451]
Issuer Delisting; Notice of Application
of New York Health Care, Inc. To
Withdraw Its Common Stock, $.01 Par
Value, From Listing and Registration
on the Boston Stock Exchange, Inc.
February 4, 2005.
On January 21, 2005, New York
Health Care, Inc., a New York
corporation (‘‘Issuer’’), filed an
application with the Securities and
Exchange Commission (‘‘Commission’’),
pursuant to Section 12(d) of the
Securities Exchange Act of 1934
(‘‘Act’’) 1 and Rule 12d2–2(d)
thereunder,2 to withdraw its common
stock, $.01 par value (‘‘Security’’), from
listing and registration on the Boston
Stock Exchange, Inc. (‘‘BSE’’ or
‘‘Exchange’’).
On January 19, 2005, the Board of
Directors (‘‘Board’’) of the Issuer
approved resolutions to withdraw the
Issuer’s Security from listing and
registration on the BSE. In making the
decision to delist the Security from the
BSE, the Issuer stated various factors,
including: (i) That the original listing of
the Security on the Exchange was
required by the underwriter of the
Issuer’s initial public offering—a
contractual obligation that has expired;
(ii) that the Security has not traded on
the Exchange from at least January 2002
to the time of the application; (iii) the
expense involved in responding to the
Exchange’s request 3 to make any
1 15
U.S.C. 78l(d).
CFR 240.12d2–2(d).
3 By letter dated December 3, 2004, the Exchange
requested that the Issuer file a listing of additional
shares form with the Exchange and pay any fees
associated therewith, and provide information
regarding: (i) The Issuer’s previously reported
delisting of its common stock from Nasdaq and the
investigation resulting from the resignation of a
former director; (ii) the business purpose of the
resignations of the Issuer’s Chief Executive Officer
and Chief Financial Officer, which are anticipated
to occur upon the completion of the Issuer’s private
placement of securities; (iii) the current number of
beneficial holders of the Issuer, and (iv) a potential
rescission right on certain shares issued to holders
of BioBalance stock. On December 20, 2004, the
Issuer requested an extension of the December 22,
2004 deadline to have more time to decide whether
to expend the time and resources necessary to
respond to the Exchange or to voluntarily delist. On
2 17
E:\FR\FM\10FEN1.SGM
10FEN1
Federal Register / Vol. 70, No. 27 / Thursday, February 10, 2005 / Notices
necessary filings and paying any
associated fees to continue listing the
Security on the Exchange; and (iv) that
the Security currently trades on the
Over-the-Counter Market on the Pink
Sheets.
The Issuer stated in its application
that it has complied with BSE
procedures for delisting by filing the
required documents governing the
withdrawal of securities from listing
and registration on the BSE.
The Issuer’s application relates solely
to withdrawal of the Security from
listing on the BSE and from registration
under Section 12(b) of the Act,4 and
shall not affect its obligation to be
registered under Section 12(g) of the
Act.5
Any interested person may, on or
before March 1, 2005, comment on the
facts bearing upon whether the
application has been made in
accordance with the rules of the BSE,
and what terms, if any, should be
imposed by the Commission for the
protection of investors. All comment
letters may be submitted by either of the
following methods:
Electronic Comments
• Send an e-mail to rulecomments@sec.gov. Please include the
File Number 1–12451 or;
Paper Comments
• Send paper comments in triplicate
to Jonathan G. Katz, Secretary,
Securities and Exchange Commission,
450 Fifth Street, NW., Washington, DC
20549–0609.
All submissions should refer to File
Number 1–12451. This file number
should be included on the subject line
if e-mail is used. To help us process and
review your comments more efficiently,
please use only one method. The
Commission will post all comments on
the Commission’s Internet Web site
(https://www.sec.gov/rules/delist.shtml).
Comments are also available for public
inspection and copying in the
Commission’s Public Reference Room.
All comments received will be posted
without change; we do not edit personal
identifying information from
submissions. You should submit only
information that you wish to make
available publicly.
The Commission, based on the
information submitted to it, will issue
an order granting the application after
the date mentioned above, unless the
December 20, 2004, the Exchange granted the
request and extended the Issuer’s time to either
respond or voluntarily delist until January 14, 2005.
4 15 U.S.C. 78l(b).
5 15 U.S.C. 78l(g).
VerDate jul<14>2003
16:20 Feb 09, 2005
Jkt 205001
Commission determines to order a
hearing on the matter.
For the Commission, by the Division of
Market Regulation, pursuant to delegated
authority.6
Jonathan G. Katz,
Secretary.
[FR Doc. E5–563 Filed 2–9–05; 8:45 am]
BILLING CODE 8010–01–P
SECURITIES AND EXCHANGE
COMMISSION
[Release No. 34–51133; File No. SR–Amex–
2004–101]
Self-Regulatory Organizations; Notice
of Filing and Order Granting
Accelerated Approval of a Proposed
Rule Change by the American Stock
Exchange LLC Relating to the Listing
and Trading of Notes Linked to the
Performance of the Dow Jones
Industrial Average
February 3, 2005.
Pursuant to Section 19(b)(1) of the
Securities Exchange Act of 1934
(‘‘Act’’),1 and Rule 19b–4 thereunder,2
notice is hereby given that on December
10, 2004, the American Stock Exchange
LLC (‘‘Amex’’ or ‘‘Exchange’’) filed with
the Securities and Exchange
Commission (‘‘SEC’’ or ‘‘Commission’’)
the proposed rule change as described
in Items I and II below, which Items
have been prepared by the Exchange.
The Commission is publishing this
notice to solicit comments on the
proposed rule change from interested
persons and is approving the proposal
on an accelerated basis.
I. Self-Regulatory Organization’s
Statement of the Terms of Substance of
the Proposed Rule Change
The Exchange proposes to list and
trade under Section 107A of the Amex
Company Guide (‘‘Company Guide’’),
notes linked to the performance of the
Dow Jones Industrial Average (‘‘DJIA’’
or ‘‘Index’’).
II. Self-Regulatory Organization’s
Statement of the Purpose of, and
Statutory Basis for, the Proposed Rule
Change
In its filing with the Commission, the
Amex included statements concerning
the purpose of, and basis for, the
proposed rule change and discussed any
comments it received on the proposed
rule change. The text of these statements
may be examined at the places specified
in Item III below. The Exchange has
PO 00000
6 17
CFR 200.30–3(a)(1).
U.S.C. 78s(b)(1).
2 17 CFR 240.19b–4.
1 15
Frm 00056
Fmt 4703
Sfmt 4703
7129
prepared summaries, set forth in
Sections A, B, and C below, of the most
significant aspects of such statements.
A. Self-Regulatory Organization’s
Statement of the Purpose of, and the
Statutory Basis for, the Proposed Rule
Change
1. Purpose
Under Section 107A of the Company
Guide, the Exchange may approve for
listing and trading securities that cannot
be readily categorized under the listing
criteria for common and preferred
stocks, bonds, debentures, or warrants.3
The Amex proposes to list for trading
under Section 107A of the Company
Guide notes issued by Citigroup, linked
to the performance of the DJIA (the
‘‘DJIA Notes’’ or ‘‘Notes’’).4 The DJIA is
determined, calculated and maintained
solely by Dow Jones.5 The Notes will
provide for a multiplier of 300%
(‘‘Upside Participation Rate’’) of any
positive performance of the DJIA during
such term subject to a maximum
payment amount or ceiling expected to
be 5.7%, which will be determined at
the time of issuance (‘‘Capped Value’’).6
3 See Securities Exchange Act Release No. 27753
(March 1, 1990), 55 FR 8626 (March 8, 1990) (order
approving File No. SR–Amex–89–29).
4 Citigroup Global Markets Holdings, Inc.
(‘‘Citigroup’’) and Dow Jones & Co. (‘‘Dow Jones’’)
have entered into a non-exclusive license agreement
providing for the use of the DJIA by Citigroup and
certain affiliates and subsidiaries in connection
with certain securities including these Notes. Dow
Jones is not responsible and will not participate in
the issuance and creation of the Notes.
5 The DJIA is a price-weighted index comprised
of 30 common stocks chosen by the editors of the
Wall Street Journal (‘‘WSJ’’) as representative of the
broad market of U.S. industry. A price-weighted
index refers to an index that assigns weights to
component stocks based on the price per share
rather than total market capitalization of such
component stock. The corporations represented in
the DJIA tend to be leaders within their respective
industries and their stocks are typically widely held
by individuals and institutional investors. Changes
in the composition of the DJIA are made solely by
the editors of the WSJ. In addition, changes to the
common stocks included in the DJIA tend to be
made infrequently with most substitutions the
result of mergers and other extraordinary corporate
actions. However, over time, changes are made to
more accurately represent the broad market of U.S.
industry. In choosing a new corporation for the
DJIA, the editors of the WSJ focus on the leading
industrial companies with a successful history of
growth and wide interest among investors. Dow
Jones, publisher of the WSJ, is not affiliated with
Citigroup and has not participated in any way in
the creation of the Notes. The number of common
stocks in the DJIA has remained at 30 since 1928,
and, in an effort to maintain continuity, the
constituent corporations represented in the DJIA
have been changed on a relatively infrequent basis.
6 Telephone conversation between Jeff Burns,
Associate General Counsel, Amex, and Florence E.
Harmon, Senior Special Counsel, Division of
Market Regulation (‘‘Division’’), SEC, dated January
31, 2005 (as to expected amount payable at maturity
under various scenarios).
E:\FR\FM\10FEN1.SGM
10FEN1
]]>Agencies
[Federal Register Volume 70, Number 27 (Thursday, February 10, 2005)]
[Notices]
[Pages 7128-7129]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E5-563]
-----------------------------------------------------------------------
SECURITIES AND EXCHANGE COMMISSION
[File No. 1-12451]
Issuer Delisting; Notice of Application of New York Health Care,
Inc. To Withdraw Its Common Stock, $.01 Par Value, From Listing and
Registration on the Boston Stock Exchange, Inc.
February 4, 2005.
On January 21, 2005, New York Health Care, Inc., a New York
corporation (``Issuer''), filed an application with the Securities and
Exchange Commission (``Commission''), pursuant to Section 12(d) of the
Securities Exchange Act of 1934 (``Act'') \1\ and Rule 12d2-2(d)
thereunder,\2\ to withdraw its common stock, $.01 par value
(``Security''), from listing and registration on the Boston Stock
Exchange, Inc. (``BSE'' or ``Exchange'').
---------------------------------------------------------------------------
\1\ 15 U.S.C. 78l(d).
\2\ 17 CFR 240.12d2-2(d).
---------------------------------------------------------------------------
On January 19, 2005, the Board of Directors (``Board'') of the
Issuer approved resolutions to withdraw the Issuer's Security from
listing and registration on the BSE. In making the decision to delist
the Security from the BSE, the Issuer stated various factors,
including: (i) That the original listing of the Security on the
Exchange was required by the underwriter of the Issuer's initial public
offering--a contractual obligation that has expired; (ii) that the
Security has not traded on the Exchange from at least January 2002 to
the time of the application; (iii) the expense involved in responding
to the Exchange's request \3\ to make any
[[Page 7129]]
necessary filings and paying any associated fees to continue listing
the Security on the Exchange; and (iv) that the Security currently
trades on the Over-the-Counter Market on the Pink Sheets.
---------------------------------------------------------------------------
\3\ By letter dated December 3, 2004, the Exchange requested
that the Issuer file a listing of additional shares form with the
Exchange and pay any fees associated therewith, and provide
information regarding: (i) The Issuer's previously reported
delisting of its common stock from Nasdaq and the investigation
resulting from the resignation of a former director; (ii) the
business purpose of the resignations of the Issuer's Chief Executive
Officer and Chief Financial Officer, which are anticipated to occur
upon the completion of the Issuer's private placement of securities;
(iii) the current number of beneficial holders of the Issuer, and
(iv) a potential rescission right on certain shares issued to
holders of BioBalance stock. On December 20, 2004, the Issuer
requested an extension of the December 22, 2004 deadline to have
more time to decide whether to expend the time and resources
necessary to respond to the Exchange or to voluntarily delist. On
December 20, 2004, the Exchange granted the request and extended the
Issuer's time to either respond or voluntarily delist until January
14, 2005.
---------------------------------------------------------------------------
The Issuer stated in its application that it has complied with BSE
procedures for delisting by filing the required documents governing the
withdrawal of securities from listing and registration on the BSE.
The Issuer's application relates solely to withdrawal of the
Security from listing on the BSE and from registration under Section
12(b) of the Act,\4\ and shall not affect its obligation to be
registered under Section 12(g) of the Act.\5\
---------------------------------------------------------------------------
\4\ 15 U.S.C. 78l(b).
\5\ 15 U.S.C. 78l(g).
---------------------------------------------------------------------------
Any interested person may, on or before March 1, 2005, comment on
the facts bearing upon whether the application has been made in
accordance with the rules of the BSE, and what terms, if any, should be
imposed by the Commission for the protection of investors. All comment
letters may be submitted by either of the following methods:
Electronic Comments
Send an e-mail to rule-comments@sec.gov. Please include
the File Number 1-12451 or;
Paper Comments
Send paper comments in triplicate to Jonathan G. Katz,
Secretary, Securities and Exchange Commission, 450 Fifth Street, NW.,
Washington, DC 20549-0609.
All submissions should refer to File Number 1-12451. This file
number should be included on the subject line if e-mail is used. To
help us process and review your comments more efficiently, please use
only one method. The Commission will post all comments on the
Commission's Internet Web site (https://www.sec.gov/rules/delist.shtml).
Comments are also available for public inspection and copying in the
Commission's Public Reference Room. All comments received will be
posted without change; we do not edit personal identifying information
from submissions. You should submit only information that you wish to
make available publicly.
The Commission, based on the information submitted to it, will
issue an order granting the application after the date mentioned above,
unless the Commission determines to order a hearing on the matter.
For the Commission, by the Division of Market Regulation,
pursuant to delegated authority.\6\
---------------------------------------------------------------------------
\6\ 17 CFR 200.30-3(a)(1).
---------------------------------------------------------------------------
Jonathan G. Katz,
Secretary.
[FR Doc. E5-563 Filed 2-9-05; 8:45 am]
BILLING CODE 8010-01-P
